Meinian Onehealth sweetens bid for iKang

Meinian Onehealth Healthcare and a group of investors have sweetened their offer to buy iKang Healthcare Group ($KANG), raising their bid to $23.50 per American Depositary Share (ADS) from the original bid of $22 per ADS. The investors include units of Ping An Insurance, Taiping Asset Management, Huatai Ruilian Fund Management, Sequoia China Investment Management and Cathay Capital Private Equity. The new bid is about 46.2% above iKang's last closing price on Aug. 28 and also comes after iKang announced it had created a poison-pill antitakeover defense. "We are optimistic about the potential of China's preventive health industry," Yu Rong, CEO of Meinian, said in a company release. "We believe that there are huge untapped market opportunities, and that the sector has entered a phase of industry consolidation." Meinian has more than 130 medical exam centers in about 80 cities throughout China and claims to have a customer base of 10 million. It was founded in 2004. In 2014 iKang went public in the U.S. on Nasdaq and raised $153 million while Meinian became listed in Shenzhen via a reverse merger with Jiangsu Sanyou Group. Release

Webinar

Using AI and RWD to Uncover Rare Disease Insights, Accelerate Commercialization and Improve Patient Outcomes

Wednesday, March 24 | 2pm ET / 11am PT

Learn how IPM.ai transformed real world data into real world insights to assist Audentes in their development of AT132 for the treatment of XLMTM. The session reviews how IPM.ia and Audentes collaborated to uncover the XLMTM patient population.